At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Slamon et al presented results from the phase III NATALEE trial, which evaluated adjuvant ribociclib plus endocrine therapy in a broad population of patients with early breast cancer who were at risk for recurrence (Abstract LBA500).
